跳至主要内容
临床试验/NCT02944682
NCT02944682已完成不适用

Household Air Pollution and Health: A Multi-country LPG Intervention Trial

Emory University7 个研究点 分布在 4 个国家目标入组 3,640 人开始时间: 2017年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
3,640
试验地点
7
主要终点
Birth weight

研究概览

简要总结

This study is a randomized controlled trial of liquefied petroleum gas (LPG) stove and fuel distribution in 3,200 households in four countries (India, Guatemala, Peru, and Rwanda). Following a common protocol, each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation) and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. The researchers estimate that 15% of households will have a second, non-pregnant older adult woman (aged 40 to <80 years) who will also be enrolled at baseline and followed during the 18-month follow-up period. To optimize intervention use, the researchers will implement behavior change strategies informed by previous experiences and formative research in Year 1. This study will assess cookstove use, conduct repeated personal exposure assessments of household air pollution, and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and systolic blood pressure in the older adult woman. Participants in India, Guatemala and Rwanda will be followed until the child is 5 years old to assess the longer-term effects of the intervention.

详细描述

Globally, nearly 3 billion people rely on solid fuels for cooking and heating, the vast majority in low- and middle-income countries (LMICs). The resulting household air pollution (HAP) is the third leading risk factor in the 2010 global burden of disease, accounting for an estimated 4.3 million deaths annually, largely among women and young children. Previous interventions have provided cleaner biomass-based cookstoves but have failed to reduce exposure to levels that produce meaningful health improvements. There have been no large-scale field trials with liquefied petroleum gas (LPG) cookstoves, likely the cleanest scalable intervention.

The aim of this study is to conduct a randomized controlled trial of LPG stove and fuel distribution in 3,200 households in four LMICs (India, Guatemala, Peru, and Rwanda) to deliver rigorous evidence regarding potential health benefits across the lifespan. Each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation) and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. In households with a second, non-pregnant older adult woman (aged 40 to <80 years) the researchers will also enroll and follow her during the 18-month follow-up period in order to assess cardiopulmonary, metabolic, and cancer outcomes. To optimize intervention use, the researchers will implement behavior change strategies. This study will assess cookstove use, conduct repeated personal exposure assessments to HAP (PM2.5, black carbon, carbon monoxide), and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage on all participants at multiple time points. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and systolic blood pressure in the older adult woman.

This study will address the following specific aims: (1) using an intent-to-treat analysis, determine the effect of a randomized LPG stove and fuel intervention on health in four diverse LMIC populations using a common protocol; (2) determine the exposure-response relationships for HAP and health outcomes; and (3) determine relationships between LPG intervention and both targeted and exploratory biomarkers of exposure/health effects.

This study will provide evidence, including costs and implementation strategies, to inform national and global policies on scaling up LPG stoves among vulnerable populations. Ultimately, this will facilitate deeper policy-level discussions as well as identify requirements for initiating and sustaining HAP interventions globally.

The intervention delivery occurred until the child was one year of age. The researchers will continue to follow participants in India, Guatemala and Rwanda until the child is 5 years old to assess the longer-term effects of the intervention. Previous evidence suggests that the benefits of reduced exposure during the first, critical year of development will continue even if the intervention ends. The researchers will continue using methods employed during the HAPIN trial period. The HAPIN trial provides a unique context in which to address these questions, particularly given the successful intervention and exposure reduction. Participants are well-characterized and health and exposures to air pollution are being documented. Critically, because of its experimental design of the trial, continued follow-up of the cohort will provide rigorous causal inferences about the effects of this 500-day intervention over the most important period of early childhood development.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • for Pregnant Women:
  • Confirmed pregnancy (hCG positive blood or urine test)
  • Aged 18 to <35 years (via self-report)
  • Uses biomass stove predominantly
  • Lives in study area
  • 9 - <20 weeks gestation confirmed by ultrasound
  • Singleton pregnancy (one fetus)
  • Viable fetus with normal fetal heart rate (120-180 beats per minute) at time of ultrasound
  • Continued pregnancy at the time of randomization confirmed by self-report
  • Agrees to participate with informed consent

排除标准

  • for Pregnant Women:
  • Currently smokes cigarettes or other tobacco products
  • Plans to move permanently outside study area in the next 12 months
  • Uses LPG stove predominantly, or is likely to use LPG predominantly in the near future
  • Inclusion Criteria for Older Adult Woman in the Same Household:
  • Aged 40 to <80 years (via self-report)
  • Exclusion Criteria for Older Adult Woman in the Same Household:
  • Currently smokes cigarettes or other tobacco products
  • Pregnant (by self-report)
  • Plans to move out of her current household in the next 12 months

研究组 & 干预措施

Liquefied petroleum gas cookstove

Experimental

Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.

干预措施: Liquefied petroleum gas (LPG) cookstove (Other)

Control

No Intervention

Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.

结局指标

主要结局

Birth weight

时间窗: Within 24 hours of birth (up to 5 months post-randomization of mother)

Birth weight is assessed by a trained nurse or health worker within 24 hours of birth. Infants are weighed naked or in a pre-weighed blanket. Weight is measured to the nearest 10 g using a digital electronic scale, if performed by the study field staff; otherwise, hospital medical records are used.

Change in Systolic Blood Pressure

时间窗: Baseline, 3, 5, 9, 12, and 18 months post-randomization (24, 36, 48, and 60 months of age)

Systolic blood pressure will be assessed in the older adult women in the intervention and control arms using automatic sphygmomanometers (Omron HEM-907XL; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.

Change in Child Linear Growth

时间窗: Birth (3-5 months post-randomization), and 3, 6, 9, 12, 24, 36, 48 and 60 months of age

Linear growth of children will be assessed in centimeters of height from the time of birth until 60 months of age.

Change in Caregiver Reported Early Childhood Development Instrument (CREDI) Score

时间窗: 3 months of age to 24 months of age

Child development will be assessed with the Caregiver Reported Early Childhood Development Instrument (CREDI). The CREDI is a population-level measure of early childhood development (ECD) for children from 0-2 years of age. The CREDI assesses 5 domains of child development: 1) motor development (fine and gross motor), 2) language development (expressive and receptive language), 3) cognitive development (executive function, problem solving and reasoning, and pre-academic knowledge), 4) socio-emotional development (emotional and behavioral self-regulation, emotional knowledge, and social competence), and 5) mental health (internalizing and externalizing behaviors). The CREDI long form has 117 items and the number of questions answered depends on the age of the child. Responses of "yes" are coded as 1 and "no" is coded as 0; certain items are reverse coded. Total raw scores increase by age (with developmental progression), and higher scores indicate increased development.

Change in Malawi Developmental Assessment Tool (MDAT) Score

时间窗: 36, 48 and 60 months of age

The MDAT measures gross motor (39 items), fine motor (42 items), language/cognition (40 items) and social skills (36 items). Originally developed and validated in rural Malawi, it has now been used in over 25 countries with more than 8,000 children as both a clinical and research tool. The MDAT is a continuous test with start and stop rules. Most items are administered directly to the child and items that are not easily observed (e.g., child speaks in full sentences; child understands sharing with others; child can dress self) are administered by parent report. Children receive either a pass or fail for each item, and summed pass scores can produce a composite score as well as domain-specific scores. Total scores range from 0 to 157 where higher scores indicate greater neurodevelopment.

Incidence of HAPIN Defined Severe Pneumonia

时间窗: Up to 12 months after birth

The number of times a child has severe pneumonia over their period of follow-up during the first year of life is assessed. For this study pneumonia criteria are adapted from the WHO classification of childhood pneumonia (2014) and there are 3 algorithms for case criteria: 1) the presence of cough and/or difficult breathing and at least 1 general danger sign plus evidence of pneumonia on lung imaging (i.e., lung ultrasound or chest x-ray), or 2) the presence of cough and/or difficult breathing and hypoxemia (measured either via pulse oximetry (SpO2), or observing a child requiring advanced respiratory support (i.e., intubation and mechanical ventilation, non-invasive ventilation with continuous or bi-level positive airway pressure support, or high-flow nasal cannula oxygen), or 3) children who die prior to evaluation but their death is attributed to pneumonia by verbal autopsy. Cases of pneumonia are recorded children present to HAPIN health facilities with respiratory symptoms.

Length-for-age z-score 2 standard deviations below the standard

时间窗: 12 months after birth

The primary outcome measured is stunting at one year of age, defined as a length-for-age z-score (LAZ) that is 2 standard deviations below the median of the growth standard. Infant length is assessed at birth and quarterly thereafter, until the child is 12 months old. Z-scores are calculated using the 2006 World Health Organization (WHO) Multi-Growth Reference Standard (MGRS).

次要结局

  • WHO Pocket Book Non-severe Pneumonia(Up to 12 months after birth)
  • WHO Pocket Book Severe Pneumonia(Up to 12 months after birth)
  • Change in Maternal Blood Pressure(Baseline (9-20 weeks gestation), 24-28 and 32-36 weeks gestation, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Diastolic blood pressure(Baseline, 3, 6, 12 and 18 months post-randomization, and at 24, 36, 48, and 60 months of age of the child)
  • Mean arterial pressure(Baseline, 3, 6, 12 and 18 months post-randomization, and at 24, 36, 48, and 60 months of age of the child)
  • Preterm birth(Up to 5 months (within 24 hours of birth, 3-5 months post randomization))
  • WHO Non-severe Pneumonia(Up to 12 months after birth)
  • WHO Severe Pneumonia(Up to 12 months after birth)
  • Hospitalization for respiratory illness(Up to 12 months after birth)
  • Hypoxemic Pneumonia(Up to 12 months after birth)
  • Change in Brachial artery reactivity testing (BART)(Baseline, 18 months post-randomization)
  • Change in Carotid intima-media thickness (CIMT)(Baseline, 18 months post-randomization, and when child is 24 months of age)
  • Change in St. George Respiratory Questionnaire (SGRQ) Score(Baseline, 18 months post-randomization)
  • Change in Short Form 36 Survey (SF-36) Score(Baseline, 18 months post-randomization)
  • Change in Weight(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Body Mass Index (BMI)(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Height(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24 months of age of the child)
  • Change in Urinary Biomarkers(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and 24 months of age of the child)
  • Change in Dried Blood Spot (DBS) Biomarkers(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24 months of age of the child)
  • Child Lung Function(36, 48 and 60 months of age)
  • Death(Up to Study Exit (up to 60 months of age of child))
  • Ultrasound or Radiograph Pneumonia(Up to 12 months after birth)
  • Fetal Growth(Baseline, Gestation Week 24-28 and Gestation Week 32-36)
  • Gestational age at birth(Up to 5 months (within 24 hours of birth, 3-5 months post randomization))
  • Change in Maternal Blood Pressure(Baseline (9-20 weeks gestation), 24-28 and 32-36 weeks gestation, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Diastolic blood pressure(Baseline, 3, 6, 12 and 18 months post-randomization, and at 24, 36, 48, and 60 months of age of the child)
  • Mean arterial pressure(Baseline, 3, 6, 12 and 18 months post-randomization, and at 24, 36, 48, and 60 months of age of the child)
  • Pulse pressure(Baseline, 3, 6, 12 and 18 months post-randomization, and at 24, 36, 48, and 60 months of age of the child)
  • Fetal Growth(Baseline, Gestation Week 24-28 and Gestation Week 32-36)
  • Gestational age at birth(Up to 5 months (within 24 hours of birth, 3-5 months post randomization))
  • Preterm birth(Up to 5 months (within 24 hours of birth, 3-5 months post randomization))
  • WHO Non-severe Pneumonia(Up to 12 months after birth)
  • WHO Severe Pneumonia(Up to 12 months after birth)
  • Hospitalization for respiratory illness(Up to 12 months after birth)
  • WHO Pocket Book Non-severe Pneumonia(Up to 12 months after birth)
  • WHO Pocket Book Severe Pneumonia(Up to 12 months after birth)
  • Hypoxemic Pneumonia(Up to 12 months after birth)
  • Ultrasound or Radiograph Pneumonia(Up to 12 months after birth)
  • Change in Brachial artery reactivity testing (BART)(Baseline, 18 months post-randomization)
  • Change in Carotid intima-media thickness (CIMT)(Baseline, 18 months post-randomization, and when child is 24 months of age)
  • Change in St. George Respiratory Questionnaire (SGRQ) Score(Baseline, 18 months post-randomization)
  • Change in Short Form 36 Survey (SF-36) Score(Baseline, 18 months post-randomization)
  • Change in Weight(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Body Mass Index (BMI)(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24, 36, 48 and 60 months of age of the child)
  • Change in Height(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24 months of age of the child)
  • Change in Urinary Biomarkers(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and 24 months of age of the child)
  • Change in Dried Blood Spot (DBS) Biomarkers(Baseline, 3, 6, 9, 12 and 18 months post-randomization, and at 24 months of age of the child)
  • Child Lung Function(36, 48 and 60 months of age)
  • Death(Up to Study Exit (up to 60 months of age of child))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thomas Clasen

Professor

Emory University

研究点 (7)

Loading locations...

相似试验